Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Biomarin has a near $3bn per annum drug franchise, and is profitable. Elliott Investment Management may be attempting to ...

Researchers have used whole-genome CRISPR interference screening to identify the “Achilles Heel” of drug-resistant ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), retaining the price ...

GRAND CAYMAN, CAYMAN ISLANDS, . (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA ...

Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ...

Cambridge, Massachusetts Tuesday, November 19, 2024, 18:00 Hrs [IST] ...

A groundbreaking study presented at the American Heart Association's Scientific Sessions 2023 unveils promising results for a ...